Pharma Update
Cycle time
Development timelines compared to industry
Roche with faster than average Phase III cycle time, but lagging in Phase II
Composite cycle time at a project level, years
Preclinical
Phl
Ph II*
Ph III Registration
Roche
Industry
2013-17
1.0
1.8
2.5
2017-21
1.1
1.9
N=48
N=45
Roche rank:
7/13
8/14
2013-17
1.0
1.9
2.3
2017-21
1.0
2.0
2.4
3.1
N=27
12/14
2.7
3.5
3.3
0.6 9.4
2.6
0.5 9.2
N=39
N=52
3/14
2/14
0.8 8.7
0.7
9.4
N=339
N=178
N=120
N=237
N=316
* Phase II cycle time encompasses Phase Ib expansions (in Oncology), single arm Phase Ils and randomized Phase Ils. A great portion of projects in Phase II are Oncology Phase Ib expansions, where a
higher SoC bar in most indications (requiring assessment of time-to-event endpoints in order to ungate a larger Phase III study) might be one of the factors contributing to longer duration over time
Composite cycle time only includes projects which successfully completed a certain phase in the time window of interest and is calculated by the sum of each phase cycle time (sum of median CT for all projects which completed Preclinical, Ph1,
Ph2, Ph3, Registration in the time window of interest, e.g., 2017-21). This method allows for a more current view of phase completion, as each phase is calculated using the most current CT window. Projects originated externally are included in the
calculation (if in-licensed and/or acquired mid-stream, CT calculated from the start of the following phase); Source: KMR
Roche
27
27View entire presentation